LLS increases maximum benefit for myeloma patients to $10,000

Feb 3 2010

The Leukemia & Lymphoma Society (LLS) is pleased to announce that, effective Feb. 1, 2010, patients with myeloma and waldenstrom macroglobulinemia will now be able to receive up to $10,000 in support to help offset the costs of prescription drug co-pays and other insurance related expenses.  Prior to this change, the maximum benefit for myeloma and waldenstrom macroglobulinemia patients was $5,000.

Patients, caregivers and healthcare professionals, may submit applications easily through the online application through the established link on the Co-Pay webpage www.lls.org/copay. Applications can also be submitted on the toll free line with a Co-Pay specialist.  Eligibility will be determined by medical and financial need.

"Receiving a diagnosis of a blood cancer such as myeloma is overwhelming and that devastating news can be compounded by an inability to afford the treatments," said Anita Welborn, senior director, patient services reimbursement programs.  "LLS is pleased to be able to help alleviate this burden for patients with this expanded benefit."

LLS' Co-Pay Assistance Program also benefits patients with chronic lymphocytic leukemia, Hodgkin and non-Hodgkin lymphoma, chronic myelogenous leukemia and myelodysplastic syndrome. Eligible patients with these diseases can now receive up to $5,000 in assistance from LLS' Co-Pay Assistance Program.